Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1580 - Primary Efficacy Results and Clinical Impact of UGT1A1 genotype on Safety from a Phase II Study of FOLFOXIRI plus bevacizumab in Patients with Metastatic Colorectal Cancer: The QUATTRO Study


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Immunotherapy;  Translational Research;  Colon and Rectal Cancer


Hideaki Bando


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


H. Bando1, T. Kato2, T. Yoshino1, K. Muro3, K. Yamazaki4, T. Yamaguchi5, E. Oki6, S. Iwamoto7, A. Tsuji8, G. Nakayama9, Y. Emi10, T. Touyama11, M. Nakamura12, M. Kotaka13, Y. Kagawa14, H. Taniguchi3, H. Sakisaka15, T. Yamanaka16, A. Kanazawa17

Author affiliations

  • 1 Department Of Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2 Department Of Surgery, National Hospital Organization Osaka National Hospital, 540-0006 - Osaka/JP
  • 3 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 4 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 5 Department Of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 113-0021 - Tokyo/JP
  • 6 Department Of Surgery And Science, Kyushu University, 812-8582 - Fukuoka/JP
  • 7 Cancer Center, Aichi Medical University, 480-1195 - Aichi/JP
  • 8 Faculty Of Medicine/graduate School Of Medicine, Kagawa University, 761-0793 - Kagawa/JP
  • 9 Department Of Gastroenterological Surgery, Nagoya University, Graduate School of Medicine, 466-8550 - Nagoya/JP
  • 10 Department Of Surgery, Saiseikai Fukuoka General Hospital, 810 0001 - FUKUOKA/JP
  • 11 Department Of Surgery, Nakagami Hospital, 904-2143 - Okinawa/JP
  • 12 Aizawa Comprehensive Cancer Center, Aizawa Hospital, 390-8510 - Matsumoto/JP
  • 13 Gastrointestinal Cancer Center, Sano Hospital, 655-0031 - Kobe/JP
  • 14 Department Of Colorectal Surgery, Kansai Rosai Hospital, 660-8511 - Amagasaki/JP
  • 15 Department Of Surgery, Kawanishi City Hospital, 666-0195 - Kawanishi/JP
  • 16 Medical Course Biostatistics, Yokohama City University School of Medicine, 236-0004 - Yokohama/JP
  • 17 Department Of Surgery, Shimane Prefectural Central Hospital, 693-8555 - Izumo/JP


Abstract 1580


The TRIBE study showed that FOLFOXIRI plus bevacizumab (Bmab) significantly improved efficacy outcomes as first-line treatment in patients (pts) with metastatic colorectal cancer. A prospective single-arm, multicenter, phase II study investigated the efficacy and safety of Japanese pts.


Pts were treated with 12 cycles of FOLFOXIRI plus Bmab as induction therapy followed by maintenance with 5-FU plus Bmab until disease progression or unacceptable toxicities. Pts with the double heterozygous or homozygous genotype of the UGT1A1 *28 and *6 polymorphisms were excluded. Prophylactic uses of G-CSF were not permitted. The primary end point was progression-free survival (PFS) rate at 10 months by investigator, which was confirmed by central assessment.


Totally, 69 pts were enrolled. The median age was 60 years, and 42 pts were male. 39 pts with the UGT1A1 single heterozygous genotype and 30 pts with wild-type were enrolled. At a median follow-up time of 19.6 months, the PFS rate at 10 months by investigator and central assessment were 75.2% (95% CI, 63.8–86.6) and 69.0% (95% CI, 56.6-81.4), respectively. The median PFS was 13.3 months (95% CI, 11.5–19.4). The response rate and the rate of early tumor shrinkage were respectively 73.9% and 71.0%, achieving R0 resection rate of 24.6%. The major grade ≥3 adverse events were neutropenia (74%), hypertension (35%), and febrile neutropenia (FN; 22%). One treatment-related death occurred. During the first 2 cycles of induction therapy, grade 4 neutropenia and FN in UGT1A1 single heterozygous pts were 46% and 26%, while those in wild-type pts were 13% and 10% (P = 0.0044 and P = 0.127). However, no association in terms of efficacy between UGT1A1 single heterozygous and wild-type pts was indicated.


The efficacy of FOLFOXIRI plus Bmab in Japanese were consistent with those of previous phase II and III studies, with manageable but different toxicity profiles in terms of grade 4 neutropenia and FN between UGT1A1 single heterozygous and wild-type pts. Prophylactic use of G-CSF in UGT1A1 single heterozygous pts was suggested considering the high incidence of grade 4 neutropenia and FN.

Clinical trial identification

UMIN000013797, NCT02246049

Legal entity responsible for the study

EPS Corporation


Chugai Pharma Pharmaceutical Co., Ltd.


T. Kato: Bayer Yakuhin, Ltd, Japan; Eli Lilly Japan K.K., Ltd.; Yakult Honsha Co., Ltd., Ltd.; Takeda Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd. K. Muro: Shionogi & Co., Ltd., MSD K.K., Daiichi Sankyo Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Gilead Sciences, Chugai Phramaceutical Co., Ltd, Takeda Pharmaceutical Company, Ltd., Eli Lilly Japan K.K., Merck Serono, Taiho, Yakult Honsha. K. Yamazaki: Honoraria: Bayer Yakuhin, Bristol-Myers Squibb Japan, Chugai Pharma, Daiichi Sankyo, Lilly Japan, Merck Serono, Takeda, Taiho Pharmaceutical, and Yakult Honsha. Research funding: Bristol-Myers Squibb Japan and Sanofi. E. Oki: Honoraria for lecturing from Bayer Yakuhin, Ltd, Japan, Eli Lilly Japan K.K, Taiho Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Merck Serono Co., Ltd., Takeda Pharmaceutical Co., Ltd., Johnson & Johnson K.K. and Chugai Pharmaceutical Co., Ltd. A. Tsuji: Honoraria Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharma, Merck Serono, Takeda Pharmaceutical, Bristol-Myers Squibb Japan. Speakers\' Bureau Chugai Pharma, Taiho Pharmaceutical, Takeda, Merck Serono. Y. Emi: Honoraria for lecturing from Chugai Pharmaceutical Co., Ltd. M. Kotaka: Chugai Pharmaceutical Co., Ltd. T. Yamanaka: Honoraria: Takeda, Chugai, Merck-Serono, Boehringer-Ingelheim, Taiho Pharmaceutical. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.